Establishment of an immune therapy register for the improvement of drug safety and treatment of patients with multiple sclerosis (REGIMS)
- The Competence Network of Multiple Sclerosis (KKNMS) and the Muenster Institute of Epidemiology and Social Medicine collaborate in the establishment of an immune therapy register (REGIMS). This register will contribute to a better knowledge of the risks and effectiveness of established and future immune therapies for multiple sclerosis (MS) and will provide valuable complementary data to pharmacovigilance programs of the federal drug agencies. Included safety studies will focus on the comparison of adverse events between patients under treatment with new compared to standard immune therapies. In the context of this project, the BIPS has contributed by evaluating whether treatment complications and serious adverse events can be analyzed based on data from the German Pharmacoepidemiological Research Database (GePaRD). Moreover, estimates of the incidence of MS in Germany have been conducted as well as comprehensive analyses on prescription patterns of drugs related to MS.
- Begin: January 2015
End: October 2015
- PD Dr. rer. nat. Oliver Riedel
- Prof. Dr. med. Klaus Berger, MD, MPH, University of Muenster, Institute of Epidemiology and Social Medicine, Domagkstr. 3, 48149 Muenster
- Prof. Dr. Klaus Berger (Institut für Epidemiologie und Sozialmedizin, Universität Münster)